Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors

Inhibitors of phosphatidylinositol 3-kinase (PI3K) and Bruton tyrosine kinase (BTK) represent a recognized option for the treatment of patients affected by indolent B cell lymphomas. However, small molecules as single agents show limited success in their ability in inducing complete responses, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Guidetti, Francesca, Arribas, Alberto J., Sartori, Giulio, Spriano, Filippo, Barnabei, Laura, Tarantelli, Chiara, Von Roemeling, Reinhard, Martinez, Elizabeth, Zucca, Emanuele, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864368/
https://www.ncbi.nlm.nih.gov/pubmed/36675328
http://dx.doi.org/10.3390/jcm12020399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864368/
https://www.ncbi.nlm.nih.gov/pubmed/36675328
http://dx.doi.org/10.3390/jcm12020399

Ejemplares similares